Phenazepam use in the state of Georgia has increasingly become a trend for a drug market looking at new and different recreational drugs. This paper examines the psychomotor effects of phenazepam on individuals and their ability to operate a motor vehicle. This study reviewed phenazepam cases of impaired drivers that were submitted to the Georgia Bureau of Investigation's Division of Forensic Sciences between March, 2010, and August, 2011. A total of 11 cases were reviewed, of which five had only phenazepam detected and six had multiple drugs detected in addition to phenazepam. Concentrations ranged from 0.04 to 3.2 mg/L, with a median of 0.17 mg/L and a mean of 0.50 mg/L (0.23 mg/L, excluding the 3.2 mg/L blood concentration). The observed effects where symptomatic of central nervous system depression with slurred speech, lack of balance, slow reactions, drowsiness and confusion. This review indicates that the use of phenazepam at concentrations similar to other low-dose benzodiazepines such as clonazepam can have a significant impact on an individual's ability to drive.

As the number of prescriptions, over-the-counter medications and drugs of abuse continue to increase, forensic laboratories are faced with the challenge of developing more comprehensive screening methods in order to detect them in whole blood samples. Another challenge faced by forensic laboratories is detecting and identifying novel synthetic compounds as they emerge and change. Traditional drug screening methods include enzyme immunoassay (EIA) and either gas or liquid chromatography paired with mass spectrometry (GC–MS or LC–MS-MS, respectively). While these methods are good, they have their disadvantages. For example, EIA requires special reagents for each drug class, GC–MS requires extensive sample preparation, and LC–MS-MS only detects drugs on a known inclusion lists of compounds of interest. Described below is the development of a robust and comprehensive screening method for drugs in whole blood samples that eliminates the aforementioned disadvantages of the traditional methods. Using a Q Exactive Focus ™ liquid chromatography-high resolution-accurate mass spectrometer (LC–HRMS-MS), a method was developed that is capable of detecting approximately 200 drugs at a concentration of 2 μg/L for most analytes. This method also employs a more automated data processing feature which reduces processing time. Finally, it has the added benefit of retroactive data analysis, which allows it to be used for unknown drug analysis as well. Used as an initial screening method, the comprehensive drug screen using LC–HRMS-MS has the potential to take on two of the most important challenges faced by forensic laboratories today.

The Georgia Bureau of Investigation utilized a silylation method of analysis for low molecular weight carboxylic acids in the past. Due to the negative impact such derivatizations can have on gas chromatography-mass spectrometry (GC-MS) systems an alternative means of analysis was investigated. The described method is a whole blood solid phase extraction of valproic acid, salicylic acid and ibuprofen utilizing butylation for sensitivity and improved chromatography by GC-MS. The method produced a limit of detection and limit of quantitation at 1 mg/L for valproic acid, 2 mg/L for salicylic acid and 0.25 mg/L for ibuprofen. The variability based upon the middle of the calibration curve estimated to be 7% for valproic acid, 8% for salicylic acid and 11% for ibuprofen established upon a 95% confidence interval, with the highest percent coefficient of variation being 5.3% for ibuprofen.

With buprenorphine use on the rise it has become more important than ever for the forensic laboratory to be capable of analyzing for it. Described is the approach used by the Georgia Bureau of Investigation for the screening and confirmation of buprenorphine in whole blood by liquid chromatography-tandem mass spectrometry (LC-MS-MS), along with case reviews for the first 2 months of method implementation. Screening by LC-MS-MS is capable of identifying buprenorphine cases at concentrations as low as 1-2 µg/L. Confirmatory testing is performed on both indicatively screened samples and cases where buprenorphine is specifically requested. Confirmatory analysis by LC-MS-MS has a limit of detection and limit of quantitation of 0.75 µg/L with estimated uncertainties of 7.2% at 1 µg/L, 3.5% at 10 µg/L and 4.8% at 20 µg/L based on a 95% confidence interval, with the highest percent coefficient of variation being 3.7% for the 1 µg/L level. Since its implementation, the laboratory has reported out nine cases for buprenorphine. Seven of those cases were detected by the initial screen and two were identified by a specific request for buprenorphine. The cases' average concentration was 4.25 µg/L with a mode of 3.1 µg/L.

No abstract